Dayra Therapeutics

Dayra Therapeutics is a biotechnology company focused on the discovery and development of oral macrocyclic peptide therapeutics for serious human diseases. Launched in November 2025 by Versant Ventures through its Frontier Discovery Engine, the company aims to bridge the gap between small molecules and biologics by creating orally bioavailable medicines with high target specificity. Dayra utilizes a proprietary platform that combines macrocycle discovery tools with advanced computational design and modeling. The company's launch was supported by a foundational research collaboration with Biogen, which provided $50 million in upfront funding to identify and optimize candidates for high-priority immunological targets. Headquartered in San Francisco, Dayra maintains research operations in Toronto and Montreal to advance its pipeline of next-generation macrocyclic therapies.